UNIVERSITÀ DEL PIEMONTE ORIENTALE

1981 - 2021

ACCADEMIA NAZIONALE DI MEDICINA

International Summer School on Immuno-Oncology: emerging targets and combination therapies

MEETING

Verbania
August 30th – September 2nd 2021

Directors
Marisa Gariglio
Alessandra Gennari
Antonio Sica

24 CME POINTS
IN-CLASS COURSE

36 CME POINTS
WEBINAR LIVE

FOR INFORMATION
www.accmed.org

ISSIO
INTERNATIONAL SUMMER SCHOOL ON IMMUNO-ONCOLOGY

Objectives

The "Summer School of Immuno-Oncology: Emerging targets and combination therapies" aims to discuss knowledge and recent advances in the field of cancer immunotherapy. A panel of national and international lecturers will cover various aspects of preclinical and clinical immuno-oncology, ranging from the study of basic pathogenetic mechanisms for the discovery of new immunotherapeutic targets to more clinical aspects related to the effectiveness of combinatorial approaches in boosting cancer immunotherapy. The school will provide young oncologists, PhDs and PhD students, involved in clinical and research projects related to cancer immunotherapy, with a solid background in novel immuno-oncology topics.
In particular, we will focus on issues related to: inflammation and cancer; the immunity-cancer interface: mutational load of the tumor and editing of immune responses; myelopoietic alterations, tumor microenvironment and anticancer immunotherapy; radioimmunotherapy and immunotherapy of blood cancers; clinical immunotherapy; antiviral response of the host and cancer development; role of immunosenescence and inflammaging in neoplasms; and immunological disorders and cancer. Furthermore, advanced knowledge on statistics will be provided for the analysis of preclinical and clinical data. The goal is to discuss the current state of knowledge in the field of cancer immunotherapy from an interdisciplinary and translational "bench-to-bedside" standpoint.

Addressed to

Physicians and Resident doctors in oncology, clinical immunology and allergology, hematology, microbiology and virology, radiotherapy; Biologists, Pharmacists, but also PhD students, students and graduates of the degree programme in Pharmaceutical Chemistry and Technology and Biotechnology.

With the patronage of

Aiom
Associazione Italiana di Oncologia Medica

NIBIT
Translational Science

SIM
SOCIETÀ ITALIANA DI MICROBIOLOGIA

PROGRAM

Monday, **30th August**

10.00 *Registration and welcome coffee*

10.30 **Opening Address**
Gian Carlo Avanzi, Marco Krengli

11.00 **Introduction to the school and programme presentation**
Marisa Gariglio, Alessandra Gennari, Antonio Sica

11.30 **Opening Lecture**
Cancer and Inflammation - Alberto Mantovani
Chairmen: Gian Carlo Avanzi, Antonio Sica

12.30 *Lunch break*

AFTERNOON SESSION
The cancer-immune system interface
Chairmen: Gianluca Aimaretti, Ciro Isidoro

14.00 **Tumor mutational load and cancer therapy**
Giovanni Germano

14.45 **Targeting adaptive immunity in cancer**
Enrico Lugli

15.30 *Coffee break*

16.00 **Professional antigen presenting cells/DC in cancer**
Silvano Sozzani

16.45 **Immune checkpoints in cancer therapy**
Andrea Anichini

17.30 **Discussion**
Facilitator: Antonio Sica

18.00 **Adjourn**

Tuesday, **31st August**

MORNING SESSION
Anticancer immunotherapies: pros and cons
Chairmen: Umberto Dianzani, Antonia Follenzi

8.40 **Lecture**
Update on anticancer immunotherapies
Paolo Antonio Ascierto

9.40 **Extracellular Matrix at the cross-road between cancer and immunity**
Mario Colombo

10.00 **Tumor microenvironment and emergency hematopoiesis**
Laura Strauss

10.30 *Coffee Break*

11.00 **Suppressor myeloid cells in cancer**
Vincenzo Bronte

11.30 **NK in cancer therapy**
Angela Santoni

12.00 **Discussion Q&A**
Facilitator: Gianluca Gaidano

12.30 **Giovanni Melillo interviewed by Pier Luigi Canonico (NO CME)**

13.00 *Lunch Break*

AFTERNOON SESSION
Hemato & Radio Immunotherapy
Chairmen: Marco Krengli, Andrea Riccardo Filippi

14.30 **Radiotherapy and immunotherapy: current knowledge of a clinical partnership**
Pierfrancesco Franco

15.00 **Radiotherapy effects on tumor micro-environment**
Andrea Riccardo Filippi

15.30 **SBRT and immunotherapy, a winning partnership?**
Davide Franceschini

15.50 *Coffee Break*

AFTERNOON SESSION
Hemato & Radio Immunotherapy
Chairmen: Gianluca Gaidano, Giovanni Martinelli

16.20 **Molecular determinants of immune-response**
Massimo Dominici

16.40 **Immune checkpoints inhibitors in liquid tumors**
Gianluca Gaidano

17.10 **CAR-T cells**
Marco Ladetto

17.30 **Discussion Q&A**
Facilitator: Giovanni Martinelli

18.15 **CME Session Adjourn**

18.30 **Cocktail with the statisticians – (NO CME)**
Chairmen: Paolo Bruzzi, Fabrizio Faggiano, Giovanni Melillo

Innovative trial design – Adaptive Immunotherapy Trials
Oriana Nanni, Valter Torri (15 min)

Endpoints & Summary Indicators in Immunotherapy Trials
Paolo Bruzzi (15 min)

Wednesday, **1st September**

MORNING SESSION

Immunotherapy in the Clinic

Chairmen: Pier Luigi Canonico, Alessandra Gennari

9.00 **Lecture**
Regulatory Process and clinical benefit
Armando Genazzani

09.40 **IO & Lung Cancer**
Silvia Novello

10.00 **IO & Urology**
Matteo Bellone

10.20 **Immunotherapy of Melanoma:**
what we already know and future perspectives
Michele Del Vecchio

10.40 *Coffee Break*

11.00 **Breast Cancer:**
evolution of innovative agents from CDK 4/6 to checkpoint inhibitors
Valentina Guarneri

11.20 **IO & Hepatocellular carcinoma**
David J. Pinato

11.40 **Innovative IO therapies in solid tumors:**
CAR-T, oncolytic viruses and beyond
Giuseppe Curigliano

12.15 **Antiandrogenic therapy in prostate cancer and COVID**
Andrea Alimonti

12.30 **Discussion Q&A**
Facilitator: Alessandra Gennari

13.00 *Lunch Break*

AFTERNOON SESSION

The complex interplay between SARS-CoV-2
and the host immune response

Chairmen: Marisa Gariglio, Santo Landolfo

14.30 **Vaccines and monoclonals to regain our freedom**
Rino Rappuoli

15.10 **SARS COV2 variants**
Nicole Fischer

15.50 **Innate RNA sensing of SARS-CoV2 and strategies of viral evasion**
John Hiscott

16.30 *Coffee Break*

17.00 **The cGAS-STING pathway in COVID-19 – protective and pathogenic potential**
Soren Paludan

17.40 **Discussion Q&A**
Facilitator: Marco De Andrea

18.00 **Adjourn**

Thursday, **2nd September**

MORNING SESSION

Immunosenescence, Inflammaging and Cancer

Chairmen: Lia Rimondini, Annalisa Chiocchetti

9.00 **Inflammaging and Cancer**
Massimiliano Bonafè

9.50 **Common mechanisms of age-related diseases: implication for disease-specific biomarkers identification**
Fabiola Olivieri

10.40 *Coffee Break*

11.10 **Genetics and Epigenetics of Aging**
Paolo Garagnani

12.00 **Discussion Q&A**
Facilitator: Ciro Isidoro

12.30 *Lunch Break*

AFTERNOON SESSION

Immunological disorders and cancer prognosis and therapy

Chairmen: Claudio Santoro, Mario Pirisi

14.00 **Allergy/autoimmunity and cancer**
Marinos Kallikourdis

14.50 **Microbioma, immunity and cancer**
Maria Rescigno

15.10 **Tertiary lymphoid structures in immunology and immunotherapy**
Catherine Fridman

15.30 **Discussion Q&A**
Facilitator: Antonio Sica

16.00 **Closing Lecture**
B cells and antibodies, the next challenge in immunotherapy
Wolf Fridman

16.30 **Adjournment**
Marisa Gariglio, Alessandra Gennari, Antonio Sica

Directors

Marisa Gariglio
Dipartimento di Medicina Traslazionale
UPO – Università del Piemonte Orientale
Novara

Alessandra Gennari
Divisione di Oncologia
Ospedale Maggiore della Carità
Dipartimento di Medicina Traslazionale
UPO – Università del Piemonte Orientale
Novara

Antonio Sica
Dipartimento di Scienze del Farmaco
UPO – Università del Piemonte Orientale
Novara

Chairmen and Speakers

Gianluca Aimaretti
Dept. Traslational Medicine
UPO, Novara, IT

Andrea Alimonti
Institute of Oncology Research
ETH Zurich, CH

Andrea Anichini
Dept. of Research, Fondazione IRCCS
Istituto Nazionale dei Tumori
Milano, IT

Paolo Antonio Ascierto
Dept. Medical Oncology and Innovative
Therapy, Fondazione Pascale IRCCS INT
Napoli, IT

Gian Carlo Avanzi
Dept. Traslational Medicine
UPO, Novara, IT

Matteo Bellone
Dept. Immunology, Transplantation
and Infectious Diseases
IRCCS Ospedale San Raffaele
Milano, IT

Massimiliano Bonafè
Dept. of Specialized
Diagnostic and Experimental Medicine
University of Bologna, IT

Vincenzo Bronte
Dept. of Pathology and Diagnostics
University of Verona, IT

Paolo Bruzzi
Epidemiologo
Genova, IT

Pier Luigi Canonico
Dept. Pharmacological Sciences
UPO, Novara, IT

Annalisa Chiocchetti
Dept. Health Sciences and CAAD
UPO, Novara, IT

Mario Colombo
Dept. of Research, Fondazione IRCCS
Istituto Nazionale dei Tumori
Milano, IT

Giuseppe Curigliano
Development of New Drugs for Innovative
Therapies
IEO, Milano, IT

Umberto Dianzani
Department of Health Sciences
UPO, Novara, IT

Michele Del Vecchio
Unit of Melanoma Medical Oncology
Department of Medical Oncology and Hematology, Fondazione IRCCS
Istituto Nazionale dei Tumori
Milano, IT

Marco De Andrea
Dept. Sciences of Public Health and Pediatrics, University of Turin, IT

Massimo Dominici
Dept. of Medical and Surgical Sciences for Children & Adults, Università degli Studi di Modena e Reggio Emilia, IT

Fabrizio Faggiano
Dept. Traslational Medicine
UPO, Novara, IT

Andrea Riccardo Filippi
Radiation Oncology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, IT

Nicole Fischer
Universitätsklinikum Hamburg-Eppendorf
Hamburg, DE

Antonia Follenzi
Department of Health Sciences
UPO, Novara, IT

Davide Franceschini
Radiotherapy and Radiosurgery Department
Humanitas Clinical and Research Hospital
IRCCS Rozzano (MI), IT

Pierfrancesco Franco
Dept. Traslational Medicine
UPO, Novara, IT

Catherine Fridman
Paris Descartes University, F

Wolf Fridman
Paris Descartes University, F

Gianluca Gaidano
Dept Traslational Medicine
UPO, Novara, IT

Paolo Garagnani
Department of Specialized
Diagnostic and Experimental Medicine
Univerity of Bologna, IT

Giovanni Germano
Department of Oncology, University of Turin
Candiolo Cancer Institute, IT

Armando Genazzani
Department of Pharmaceutical Sciences
UPO, Novara, IT

Valentina Guarneri
Unit of Medical Oncology 2, IOV Veneto
Padova, IT

John Hiscott
Instituto Pasteur, Roma, IT

Ciro Isidoro
Dept. of Health Science
UPO, Novara, IT

Marinos Kallikourdis
Department of Biomedical Sciences
Humanitas University and Adaptive Immunity Laboratory
Humanitas Research Hospital
Milano, IT

Marco Krengli
Dept Traslational Medicine
UPO, Novara, IT

Marco Ladetto
Dept. of Hematology, UPO, Alessandria, IT

Santo Landolfo
Department of Public Health and Pediatrics
University of Turin, IT

Enrico Lugli
Laboratory of Translational Immunology
Humanitas Clinical and Research Center
Rozzano (MI), IT

Alberto Mantovani
Scientific Director
Humanitas Clinical and Research Center
Rozzano (MI), IT

Giovanni Martinelli
Scientific Director, IRST
Meldola (FC), IT

Giovanni Melillo
Vice President. Immuno-oncology
Global Medical Affairs,
AstraZeneca Oncology
Gaithersburg, Maryland, USA

Oriana Nanni
Unit of Biostatistics and Clinical trials
IRST IRCCS, Meldola (FC), IT

Silvia Novello
Department of Oncology
University of Turin, IT

Fabiola Olivieri
Department of Clinical and Molecular
Sciences, UNIPM, IT

Soren Paludan
Department of Biomedicine
Aarhus University, DK

David J. Pinato
Faculty of Medicine
Department of Surgery & Cancer
Imperial College, UK

Mario Pirisi
Dept Traslational Medicine
UPO, Novara, IT

Rino Rappuoli
GSK Vaccines, Siena, Italy
MAD Lab (TLS)
Siena, IT

Lia Rimondini
Dept. of Health Science
UPO, Novara, IT

Maria Rescigno
Humanitas Clinical and Research Center
IRCCS, Milano, IT

Angela Santoni
Dept. of Molecular Medicine
University La Sapienza
Roma, IT

Claudio Santoro
Dept. Health Sciences and CAAD
UPO, Novara, IT

Laura Strauss
EMD Serono Research Center
Billerica, Massachusetts, USA

Silvano Sozzani
Dept. of Molecular Medicine
University La Sapienza
Roma, IT

Valter Torri
Laboratory of Methodology for Clinical
Research, Istituto Mario Negri IRCCS
Milano, IT

Access mode

To ensure compliance with the health provisions regarding Covid 19, the meeting will be held both as an in-class course and as a live webinar.

The **in-class course** will take place at the venue specified underneath. Please note that due to COVID mitigation measures, Only a limited number of attendees will be accepted.

The **LIVE Webinar** will allow participants to attend the meeting from remote.

When registering, it is necessary to select the desired participation mode (in-class or remote). Registration for the activity can only take place online, no registrations will be accepted at the meeting venue.

Participants who decide to follow the LIVE webinar, will need a good Internet connection and a device (PC, Smartphone, Tablet) capable of running an updated Internet browser (e.g. Chrome or Firefox).

AccMed will organize the event exclusively in digital mode in case of worsening of the current COVID-19 emergency. In this case, AccMed will inform speakers and participants.

The official language of the course is English. No simultaneous translation will be provided.

Registration

The registration fees are:
€ 300,00 In-class course
€ 200,00 In-class course for UPO Staff & Students
€ 100,00 LIVE Webinar

Online registration at **https://summerschool.accmed.org/** within 20th August;
the application will be completed only after the payment of the registration fee.

Cancellation

In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be reimbursed.

CME In-Class Course

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-325502): **24 CME points**. Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

The credit certification for the webinar is subject to:
- Professions/specializations should correspond to those which have been accredited for CME
- attendance at the 100% of the event
- the completion of the Meeting evaluation online form;
- completion of the final test (at least 75% of correct answers). 1 attempt admitted.

The test and the meeting evaluation form must be completed within 3 days from the end of the event.

CME Webinar live

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-325681): **36 CME points**. Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

The credit certification for the webinar is subject to:
- Professions/specializations should correspond to those which have been accredited for CME
- attendance at the live webinar on the platform fad.accmed.org;
- the completion of the Meeting evaluation online form;
- completion of the final test (at least 75% of correct answers). 5 attempts admitted.

The test and the meeting evaluation form must be completed within 3 days from the end of the event.

Meeting Venue

Villa San Remigio
Università del Piemonte Orientale
Via San Remigio 20
28922 Verbania

Information and registration

segreteriacorsi@accmed.org
Tel 010 83794238
Fax 010 83794260

Promoted by

Accademia Nazionale di Medicina
www.accmed.org
Direttore Generale Stefania Ledda

Logistics and Technology

Forum Service
Via Martin Piaggio 17/8
16122 Genova

With the unrestricted sponsorship of

MAJOR SPONSOR

Bristol Myers Squibb™

Roche

SPONSOR

AstraZeneca

BeiGene

Eisai

Human Health Care

Lilly

MSD